Opthea (ASX:OPT) - CEO & Managing Director, Dr Megan Baldwin
CEO & Managing Director, Dr Megan Baldwin
Source: The Victorian Connection
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Clinical stage biopharmaceutical company Opthea (OPT) has finalised the design of two pivotal phase three trials of OPT-302
  • In separate trials, the company will assess the drug candidate in combination with Lucentis and Eylea standard of care treatments in patients with wet age-related macular degeneration (AMD)
  • The trial design was finalised in consultation with the FDA as well as the EMA and has been submitted to the relevant regulatory authorities
  • Opthea maintains it’s on track to initiate the trials in the first quarter of the 2021 calendar
  • Shares closed 5.3 per cent lower at $1.60

Opthea (OPT) has finalised the design of two pivotal phase three trials of OPT-302 in patients with wet age-related macular degeneration (AMD).

In separate trials, the company will assess the drug candidate in combination with Lucentis and Eylea standard of care treatments in study’s called ShORe and COAST, respectively.

Each trial will be rolled out at multiple centres globally and enrol approximately 990 patients each to test the efficacy and safety of the combinations.

The clinical stage biopharmaceutical company finalised the trial design in consultation with the FDA, the EMA and thought leaders in the field.

“With the achievement of other key start-up milestones, including successful scale-up of manufacturing and fill-finish of OPT-302 drug product for use in the trials, we now excitedly look forward to initiating the pivotal Phase 3 studies that are designed to support potential marketing approval of OPT-302 for the treatment of wet AMD,” added CEO Dr Megan Baldwin.

The trial protocols are now been submitted to relevant regulatory agencies, institutional review boards and human research ethics committees for consideration.

Opthea maintains it’s on track to initiate the trials in the first quarter of the 2021 calendar.

Shares closed 5.3 per cent lower at $1.60.

OPT by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…